Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcom
After the identification of discrete relapse-risk categories in patients with acute promyelocytic le...
Pediatric acute promyelocytic leukemia (APL), a rare childhood neoplasm, can be cured with all-trans...
After the identification of discrete relapse-risk categories in patients with acute promyelocytic le...
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracyclin...
A risk-adapted strategy based on all-trans retinoic acid (ATRA) and anthracycline monochemotherapy (...
A risk-adapted strategy based on all-trans retinoic acid (ATRA) and anthracycline monochemotherapy (...
A previous report of the Programa de Estudio y Tratamiento de las Hemopatias Malignas (PETHEMA) Grou...
A previous report of the Programa de Estudio y Tratamiento de las Hemopatias Malignas (PETHEMA) Grou...
Cure of acute promyelocytic leukemia (APL) is now a possibility for most patients through the use of...
Cure of acute promyelocytic leukaemia (APL) is now a reality for most patients through the use of co...
Acute promyelocytic leukemia (APL) was initially described as a distinct clinical entity in 1957, on...
Pediatric acute promyelocytic leukemia (APL) can be cured with all-trans retinoic acid (ATRA) and an...
Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been considered, even in the all-t...
After the identification of discrete relapse-risk categories in patients with acute promyelocytic le...
Acute promyelocytic leukemia is characterized by the reciprocal translocation of chromosomes 15 and ...
After the identification of discrete relapse-risk categories in patients with acute promyelocytic le...
Pediatric acute promyelocytic leukemia (APL), a rare childhood neoplasm, can be cured with all-trans...
After the identification of discrete relapse-risk categories in patients with acute promyelocytic le...
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracyclin...
A risk-adapted strategy based on all-trans retinoic acid (ATRA) and anthracycline monochemotherapy (...
A risk-adapted strategy based on all-trans retinoic acid (ATRA) and anthracycline monochemotherapy (...
A previous report of the Programa de Estudio y Tratamiento de las Hemopatias Malignas (PETHEMA) Grou...
A previous report of the Programa de Estudio y Tratamiento de las Hemopatias Malignas (PETHEMA) Grou...
Cure of acute promyelocytic leukemia (APL) is now a possibility for most patients through the use of...
Cure of acute promyelocytic leukaemia (APL) is now a reality for most patients through the use of co...
Acute promyelocytic leukemia (APL) was initially described as a distinct clinical entity in 1957, on...
Pediatric acute promyelocytic leukemia (APL) can be cured with all-trans retinoic acid (ATRA) and an...
Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been considered, even in the all-t...
After the identification of discrete relapse-risk categories in patients with acute promyelocytic le...
Acute promyelocytic leukemia is characterized by the reciprocal translocation of chromosomes 15 and ...
After the identification of discrete relapse-risk categories in patients with acute promyelocytic le...
Pediatric acute promyelocytic leukemia (APL), a rare childhood neoplasm, can be cured with all-trans...
After the identification of discrete relapse-risk categories in patients with acute promyelocytic le...